Evidence map›Paper›PMID 7908322›Full record

ArticleThe Journal of experimental medicine1994

Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones.

R Manetti, F Gerosa, M G Giudizi, R Biagiotti, P Parronchi, M P Piccinni, S Sampognaro, E Maggi, S Romagnani, G Trinchieri

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
17.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 436 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  17. Article
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

R ManettiDivision of Clinical Immunology and Allergy, University of Florence, Italy.
F Gerosa
M G Giudizi
R Biagiotti
P Parronchi
M P Piccinni
S Sampognaro
E Maggi
S Romagnani
G Trinchieri
University of Florence · IT

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Maureen E. Murphy · 1985 to 2026
$75.9M
CELL-MEDIATED CYTOTOXICITY IN HUMANSR01CA020833 · NCI · WISTAR INSTITUTE · PI KAUFMAN, RUSSEL E. · 1985 to 2003
$1.9M
DIFFERENTIATION AND FUNCTION OF MONOCYTESR01CA032898 · NCI · WISTAR INSTITUTE · PI SANTOLI, DANIELA · 1985 to 1994
–
CELL-MEDIATED CYTOTOXICITY IN HUMANSR37CA020833 · NCI · WISTAR INSTITUTE · PI TRINCHIERI, GIORGIO · 1990 to 1998
–
NCI NIH HHS CA-10815NCI NIH HHS CA-20833NCI NIH HHS CA-32898
6 · The paper itself

Abstract

Interleukin 12 (IL-12) facilitates the generation of a T helper type 1 (Th1) response, with high interferon gamma (IFN-gamma) production, while inhibiting the generation of IL-4-producing Th2 cells in polyclonal cultures of both human and murine T cells and in vivo in the mouse. In this study, we analyzed the effect of IL-12, present during cloning of human T cells, on the cytokine profile of the clones. The culture system used allows growth of clones from virtually every T cell, and thus excludes the possibility that selection of precommitted Th cell precursors plays a role in determining characteristics of the clones. IL-12 present during the cloning procedures endowed both CD4+ and CD8+ clones with the ability to produce IFN-gamma at levels severalfold higher than those observed in clones generated in the absence of IL-12. This priming was stable because the high levels of IFN-gamma production were maintained when the clones were cultured in the absence of IL-12 for 11 d. The CD4+ and some of the CD8+ clones produced variable amounts of IL-4. Unlike IFN-gamma, IL-4 production was not significantly different in clones generated in the presence or absence of IL-12. These data suggest that IL-12 primes the clone progenitors, inducing their differentiation to high IFN-gamma-producing clones. The suppression of IL-4-producing cells observed in polyclonally generated T cells in vivo and in vitro in the presence of IL-12 is not observed in this clonal model, suggesting that the suppression depends more on positive selection of non-IL-4-producing cells than on differentiation of individual clones. However, antigen-specific established Th2 clones that were unable to produce IFN-gamma with any other inducer did produce IFN-gamma at low but significant levels when stimulated with IL-12 in combination with specific antigen or insoluble anti-CD3 antibodies. This induction of IFN-gamma gene expression was transient, because culture of the established clones with IL-12 for up to 1 wk did not convert them into IFN-gamma producers when stimulated in the absence of IL-12. These results suggest that Th clones respond to IL-12 treatment either with a stable priming for IFN-gamma production or with only a transient low level expression of the IFN-gamma gene, depending on their stage of differentiation.

Indexed as

AnimalsAntibodiesCD3 ComplexCD4 AntigensCD8 AntigensCell DifferentiationClone CellsHumansInterferon-gammaInterleukin-12Interleukin-4InterleukinsMiceT-Lymphocytes, Helper-InducerAntibodiesCD3 ComplexCD4 AntigensCD8 AntigensInterferon-gammaInterleukin-12Interleukin-4Interleukins

Identifiers

PMID7908322
PMCPMC2191437
OpenAlexW1995700626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.